SVB Leerink Maintains Market Perform on Abiomed, Raises Price Target to $375
SVB Leerink analyst Danielle Antalffy maintains Abiomed (NASDAQ:ABMD) with a Market Perform and raises the price target from $335 to $375.
Abiomed Q1 Adj. EPS $1.10 Beats $1.05 Estimate, Sales $252.60M Beat $240.91M Estimate
Abiomed (NASDAQ:ABMD) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $1.05 by 4.76 percent. This is a 89.66 percent increase over earnings of $0.58 per share from the same
SVB Leerink Maintains Market Perform on Abiomed, Lowers Price Target to $335
SVB Leerink analyst Danielle Antalffy maintains Abiomed (NASDAQ:ABMD) with a Market Perform and lowers the price target from $355 to $335.
Abiomed Receives FDA Pre-Market Approval For Impella RP With SmartAssist
Abiomed's (NASDAQ:ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe and effective to treat acute right heart
Deutsche Bank Initiates Coverage On Abiomed with Buy Rating, Announces Price Target of $360
Deutsche Bank analyst Pito Chickering initiates coverage on Abiomed (NASDAQ:ABMD) with a Buy rating and announces Price Target of $360.
Abiomed Earlier Issued FY22 Guidance; Sees Sales $990M-$1.03B vs $998.13M Est.
FISCAL YEAR 2022 OUTLOOK
The company anticipates fiscal year 2022 global revenue to be in the range of $990 million to $1,030 million, representing 17% to 22% growth compared